BR112014028951A8 - Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor - Google Patents

Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor

Info

Publication number
BR112014028951A8
BR112014028951A8 BR112014028951A BR112014028951A BR112014028951A8 BR 112014028951 A8 BR112014028951 A8 BR 112014028951A8 BR 112014028951 A BR112014028951 A BR 112014028951A BR 112014028951 A BR112014028951 A BR 112014028951A BR 112014028951 A8 BR112014028951 A8 BR 112014028951A8
Authority
BR
Brazil
Prior art keywords
vector
nucleic acid
acid sequence
composition
ledgf peptides
Prior art date
Application number
BR112014028951A
Other languages
English (en)
Other versions
BR112014028951A2 (pt
Inventor
K Upadhyay Arun
Rinku Baid
Sarath Yandrapu
B Kompella Uday
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/065620 external-priority patent/WO2013074988A1/en
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of BR112014028951A2 publication Critical patent/BR112014028951A2/pt
Publication of BR112014028951A8 publication Critical patent/BR112014028951A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor. a presente invenção refere-se aos peptídeos de ledgf com atividade de agregação antiproteína e métodos de uso. os peptídeos de ledgf descritos aqui demonstram uma capacidade para tratar doenças degenerativas e doenças com vários estresses celulares, incluindo estresse oxidativo e estresse de proteína-agregação. em adição, formulações de liberação prolongada, incluindo formulações apropriadas para administração oftálmica são providas.
BR112014028951A 2012-05-21 2013-05-21 Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor BR112014028951A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649847P 2012-05-21 2012-05-21
PCT/US2012/065620 WO2013074988A1 (en) 2011-11-17 2012-11-16 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
PCT/US2013/042074 WO2013177198A1 (en) 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders

Publications (2)

Publication Number Publication Date
BR112014028951A2 BR112014028951A2 (pt) 2017-07-25
BR112014028951A8 true BR112014028951A8 (pt) 2021-09-14

Family

ID=49624295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028951A BR112014028951A8 (pt) 2012-05-21 2013-05-21 Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor

Country Status (12)

Country Link
US (2) US9526760B2 (pt)
EP (1) EP2852399B1 (pt)
JP (2) JP6632376B2 (pt)
CN (2) CN104470534A (pt)
AU (1) AU2013266468B2 (pt)
BR (1) BR112014028951A8 (pt)
CA (1) CA2873771A1 (pt)
DK (1) DK2852399T3 (pt)
ES (1) ES2791251T3 (pt)
IN (1) IN2014MN02461A (pt)
RU (1) RU2617964C2 (pt)
WO (1) WO2013177198A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470534A (zh) * 2012-05-21 2015-03-25 科罗拉多大学董事会 用于治疗退变性病症的ledgf肽及其制剂
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
JP2021528498A (ja) * 2018-06-22 2021-10-21 ビオラリクス ベー．フェー． 経口投与用生物学的ポリマーの製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US7708915B2 (en) * 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2003265576A1 (en) 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
WO2004029246A2 (en) 2002-09-26 2004-04-08 K.U.Leuven Research And Development Integrase cofactor
AU2003298786A1 (en) * 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
JP2008512984A (ja) * 2004-05-28 2008-05-01 ダナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の同定、評価、予防および治療のための組成物、キットおよび方法
CA2635534C (en) 2005-12-30 2014-07-29 Neurotech Usa Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
EP2057465A4 (en) * 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
WO2008053478A2 (en) * 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2008103265A2 (en) * 2007-02-16 2008-08-28 The Brigham And Women's Hospital, Inc. Methods of using ledgf/p75
PL2318032T3 (pl) * 2008-06-26 2012-08-31 Orphazyme Aps Zastosowanie hsp70 jako regulatora aktywności enzymatycznej
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
CA2840590C (en) * 2011-07-01 2018-09-04 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
CN104470534A (zh) * 2012-05-21 2015-03-25 科罗拉多大学董事会 用于治疗退变性病症的ledgf肽及其制剂

Also Published As

Publication number Publication date
AU2013266468B2 (en) 2017-11-09
CA2873771A1 (en) 2013-11-28
CN110054677A (zh) 2019-07-26
JP2015519343A (ja) 2015-07-09
AU2013266468A1 (en) 2014-12-18
US20170129929A1 (en) 2017-05-11
US9526760B2 (en) 2016-12-27
JP6632376B2 (ja) 2020-01-22
WO2013177198A1 (en) 2013-11-28
ES2791251T3 (es) 2020-11-03
EP2852399A4 (en) 2016-03-23
US10221226B2 (en) 2019-03-05
IN2014MN02461A (pt) 2015-07-10
RU2617964C2 (ru) 2017-04-28
JP2018172386A (ja) 2018-11-08
RU2014151603A (ru) 2016-07-10
BR112014028951A2 (pt) 2017-07-25
EP2852399A1 (en) 2015-04-01
DK2852399T3 (da) 2020-05-04
EP2852399B1 (en) 2020-02-19
CN104470534A (zh) 2015-03-25
US20150147404A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
BR112012018669A2 (pt) Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
CR20140586A (es) Celulas para producir iduronato-2-sulfatasa recombinante
BR112015002765A2 (pt) proteína de fusão, polinucleotídeo, vetor, célula hospedeira, métodos para produzir a proteína de fusão, de tratamento de uma doença em um indivíduo e para ativação seletiva in vitro ou in vivo de células reguladoras, composição farmacêutica, uso da proteína de fusão e invenção.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112014022788A2 (pt) peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro
BR112014018475A8 (pt) Compostos de imidazopirrolidinona, suas formas cristalinas e seu uso, e composição farmacêutica
EA201491644A1 (ru) Фармацевтические композиции
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
CO7131381A2 (es) Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
UY34663A (es) Acido nucleico y proteina recombinante del gen de la endotoxina axmi345, vectores, células, composiciones y métodos para proteger plantas
AR092879A1 (es) Proteinas de fusion de g3p como agentes de union a amiloide
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
AR089752A1 (es) Anticuerpos anti-lrp5 y metodos de uso
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
UY34662A (es) Acido nucleico y proteina recombinante del gen de la toxina axmi335, vectores, células, composiciones y métodos para proteger plantas
BR112014028951A8 (pt) Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2671 DE 15-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.